Statin Drug Use and the Risk of type 2 Diabetes Mellitus: Evidence-based Revision
DOI:
https://doi.org/10.5712/rbmfc11(38)1178Keywords:
Diabetes Mellitus, Type 2. Hydroxymethylglutaryl-CoA Reductase Inhibitors. Incidence.Abstract
Objective: To investigate the relationship between statin administration and the incidence of Diabetes Mellitus type 2. Methods: A systematic review of the literature was conducted using the following databases National Guidelines Clearinghouse, Cochrane Lybrary, Trip database, PubMed and MedLine using the MeSH terms “Diabetes Mellitus Type 2” and “Hydroxymethylglutaryl-CoA Reductase Inhibitors”. Systematic reviews, meta-analyses and randomized controlled trials analyzing the incidence of type 2 diabetes in statin users compared with placebo were included. Results: We selected 10 articles (1 meta-analysis and 9 randomized controlled trials). Evidence suggests that the use of statins is associated with an increased incidence of type 2 diabetes compared to placebo in most studies, especially at high dosages. Conclusion: The risk of incidence of type 2 diabetes should be considered especially when prescribing statins to patients with low cardiovascular risk (SOR A), despite the fact that selected studies present some limitations (heterogeneous methodology, and mostly observational).
Downloads
Metrics
References
Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535-45. DOI: http://dx.doi.org/10.1016/j.jacc.2010.10.047 DOI: https://doi.org/10.1016/j.jacc.2010.10.047
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42. DOI: http://dx.doi.org/ 10.1007/s00125-014-3409-3.
Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98-107. DOI: http://dx.doi.org/10.1016/j.diabres.2009.10.008 DOI: https://doi.org/10.1016/j.diabres.2009.10.008
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-24. DOI: http://dx.doi.org/10.1093/qjmed/hcq165 DOI: https://doi.org/10.1093/qjmed/hcq165
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004;69(3):548-56. PMID: 14971837 DOI: http://dx.doi.org/10.3122/jabfm.17.1.59 DOI: https://doi.org/10.3122/jabfm.17.1.59
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123-30. DOI: http://dx.doi.org/10.1016/j.amjcard.2012.12.037 DOI: https://doi.org/10.1016/j.amjcard.2012.12.037
Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58(3):303-9. DOI: http://dx.doi.org/10.1111/j.1365-2125.2004.02142.x DOI: https://doi.org/10.1111/j.1365-2125.2004.02142.x
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172(2):144-52. DOI: http://dx.doi.org/10.1001/archinternmed.2011.625 DOI: https://doi.org/10.1001/archinternmed.2011.625
Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231-8. DOI: http://dx.doi.org/10.1016/j.jacc.2012.05.019 DOI: https://doi.org/10.1016/j.jacc.2012.05.019
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. DOI: http://dx.doi.org/10.1136/bmj.f2610 DOI: https://doi.org/10.1136/bmj.f2610
Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236-40. DOI: http://dx.doi.org/10.2337/dc12-1756 DOI: https://doi.org/10.2337/dc12-1756
Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country. PLoS One. 2013;8(8):e71817. DOI: http://dx.doi.org/10.1371/journal.pone.0071817 DOI: https://doi.org/10.1371/journal.pone.0071817
Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, Tu JV. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes. 2013;6(3):315-22. DOI: http://dx.doi.org/10.1161/CIRCOUTCOMES.111.000015 DOI: https://doi.org/10.1161/CIRCOUTCOMES.111.000015
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al.; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244. DOI: http://dx.doi.org/10.1136/bmj.g3244 DOI: https://doi.org/10.1136/bmj.g3244
Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink. BMC Cardiovasc Disord. 2014;14:85. DOI: http://dx.doi.org/10.1186/1471-2261-14-85 DOI: https://doi.org/10.1186/1471-2261-14-85
Koh KK, Lim S, Sakuma I, Quon MJ. Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol. 2012;154(2):97-101. DOI: http://dx.doi.org/10.1016/j.ijcard.2011.09.002 DOI: https://doi.org/10.1016/j.ijcard.2011.09.002
Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342-7. DOI: http://dx.doi.org/10.4093/dmj.2013.37.6.415. DOI: https://doi.org/10.4093/dmj.2013.37.6.415
Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366(19):1752-5. DOI: http://dx.doi.org/10.14496/dia.41040851167.17. DOI: https://doi.org/10.14496/dia.41040851167.17
Pani LN, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care. 2008;31(3):386-90. DOI: http://dx.doi.org/10.2337/dc07-1934 DOI: https://doi.org/10.2337/dc07-1934
Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care. 2007;30(2):228-33. DOI: http://dx.doi.org/10.2337/dc09-0896. DOI: https://doi.org/10.2337/dc09-0896
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S151-6. DOI: http://dx.doi.org/10.2337/dc09-S301 DOI: https://doi.org/10.2337/dc09-S301
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.
